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Abstract
Background: The presence of any underlying heart condition could influence outcomes during the 
coronavirus disease 2019 (COVID-19). 
Methods: The registry HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19, 
NCT04334291) is an international ambispective study, enrolling COVID-19 patients discharged from 
hospital, dead or alive.
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Results: HOPE enrolled 2798 patients from 35 centers in 7 countries. Median age was 67 years (IQR: 
53.0–78.0), and most were male (59.5%). A relevant heart disease was present in 682 (24%) cases. These 
were older, more frequently male, with higher overall burden of cardiovascular risk factors (hypertension, 
dyslipidemia, diabetes mellitus, smoking habit, obesity) and other comorbidities such renal failure, lung, 
cerebrovascular disease and oncologic antecedents (p < 0.01, for all). The heart cohort received more cor-
ticoids (28.9% vs. 20.4%, p < 0.001), antibiotics, but less hydroxychloroquine, antivirals or tocilizumab. 
Considering the epidemiologic profile, a previous heart condition was independently related with short-
term mortality in the Cox multivariate analysis (1.62; 95% CI 1.29–2.03; p < 0.001). Moreover, heart 
patients needed more respiratory, circulatory support, and presented more in-hospital events, such heart 
failure, renal failure, respiratory insufficiency, sepsis, systemic infammatory response syndrome and clini-
cally relevant bleedings (all, p < 0.001), and mortality (39.7% vs. 15.5%; p < 0.001).
Conclusions: An underlying heart disease is an adverse prognostic factor for patients suffering  
COVID-19. Its presence could be related with different clinical drug management and would benefit 
from maintaining treatment with angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers during in-hospital stay. 
Trial Numbers: NCT04334291/EUPAS34399. (Cardiol J 2021; 28, 2: 202–214)
Key words: COVID-19, mortality, cardiology, registry, prognosis, heart disease 
Introduction
The recent outbreak of a zoonotic viral disease 
named coronavirus disease 2019 (COVID-19) [1] 
has been declared a pandemic by World Health Or-
ganization (WHO) [2]. With important morbimor-
tality [3], some early-published data have already 
pointed-out previous or underlying heart condi-
tions to be at higher risk for worse outcomes [4, 5]. 
Moreover, according to the American Centers for 
Disease Control and Prevention, elderly patients 
with comorbidities are at higher risk of becoming 
infected with COVID-19, especially those with cor-
onary heart disease, hypertension, or diabetes [6]. 
In fact, some authors have suggested that the mor-
tality rate of this respiratory-borne coronavirus or 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) could be even higher in those with 
previous cardiovascular diseases than in patients 
with previous chronic respiratory diseases [7]. 
Furthermore, this is relevant since an important 
percentage of patients admitted for COVID-19 will 
present with an underlying cardiac problem. In 
a recent Chinese series, 25% had heart diseases, 
44% had arrhythmias, and 58% had hypertension [8]. 
Additionally, there is preliminary evidence sug-
gesting that the responsible virus affects primarily 
the cardiovascular system and the heart itself with 
direct myocardial injury among other deleterious 
mechanisms [9, 10]. 
Taken together, to sum up, there is growing 
evidence that underlying cardiovascular conditions 
lead to a higher likelihood of COVID-19 infection, 
more severe disease progression, and higher risk 
for mortality [11]. Moreover, the pandemic has 
posed a major impact in the treatment of regular 
heart diseases [12]. 
We analyze herein, the clinical profile, pres-
entation and influence of previous treatments, 
primarily focusing on the mortality of patients 
with any underlying heart condition hospitalized 
because of COVID-19. 
Methods
The present study was approved by the ethics 
committee of the promoting center, and was ap-
praised and accepted by institutional board or local 
committees as well. Written informed consent was 
waived because of its anonymized observational 
design. All local principal researchers reviewed 
the draft and vouch for the accuracy and veracity 
of data. A complete list of hospitals, investigators, 
collaborators and definitions is available in the 
Supplementary Appendix. 
Study design and participation criteria
The registry HOPE-COVID-19 (Health 
Outcome Predictive Evaluation for COVID-19, 
NCT04334291) is an international investigator-
initiated study without conflicts of interest [13]. 
It was designed as an ambispective cohort, real 
life all-comers type, without any financial remu-
neration for researchers. Patients were eligible for 
enrollment when discharged after an in-hospital 
admission with a positive COVID-19 test or if their 
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attending physicians considered them highly likely 
to have presented the infection. Confirmed cases 
were those with positive throat swab samples tested 
using real-time reverse transcriptase–polymerase 
chain reaction assays according to the WHO recom-
mendations. All decisions and clinical procedures 
were performed by the attending physician team 
independently of this study following the local regu-
lar practice and protocols. The data was collected in 
electronic format in a secure online database (www.
HopeProjectMD.com). The information presented 
here correspond to the HOPE COVID-19 Registry 
with a cutoff performed on April 18th, 2020. 
Definitions, objectives and study outcomes
A pragmatic definition of heart disease was 
adopted and divided into various groups according 
to the local research team, led by two experienced 
physicians. Any heart disease was considered 
when it was stated in the clinical history and/or 
the patient was receiving medication for that pur-
pose. The following categories for the main heart 
problem of every patient were accepted: arrhyth-
mias, coronary artery disease, heart failure or car-
diomyopathy, heart valve disease, combined (when 
various of the former problems were present to 
a clinically relevant degree) and non-specified or other 
different from the mentioned groups (i.e. congenital 
heart disease). Study definitions are available in the 
appendix and online in the study webpage. 
The objectives were:
 — comparing the epidemiological and clinical pro-
files and management of COVID-19 patients 
with vs. without previous heart disease;
 — determining the prognostic impact of an un-
derlying heart disease on mortality;
 — identifying independent predictors of mortality 
in the group with underlying heart disease.
The reference primary end-point was con-
sidered all-cause mortality. Other events were 
recorded as secondary end-points, such as invasive 
mechanical ventilation, non-invasive mechani-
cal ventilation, prone, respiratory insufficiency, 
heart failure, renal failure, upper respiratory tract 
involvement, pneumonia, sepsis, systemic inflam-
matory response syndrome, clinically relevant 
bleeding, hemoptysis and embolic events. Events 
were allocated following local researcher criteria 
upon HOPE COVID-19 registry definitions. 
Statistical analysis
Data are presented as mean ± standard deviation 
for continuous variables with a normal distribution, 
median (interquartile range [IQR]) for continuous 
variables with a non-normal distribution, and as 
frequency (%) for categorical variables. The Student 
t-test and the Mann-Whitney U-test were used to 
compare continuous variables with normal and non-
normal distributions, when needed. The Chi-squared-
test was used to compare categorical variables. Given 
the multiplicity of variables, only factors with p < 0.05 
on the mentioned univariate analysis were entered 
into the Cox multivariate analysis. Mortality analysis 
was performed using the Kaplan-Meier estimates and 
log-rank tests to compare factors. Statistical analysis 
was completed with SPSS statistics v24.0 (SPSS, Inc., 
Chicago, IL, USA) in all analyses. All tests were two-
-sided, and a p-value less than 0.05 was considered 
statistically significant.
Results
Finally, 2798 patients were enrolled in HOPE 
registry up to 18th April, 2020, from 35 centers in 
25 cities and 7 countries (Canada, China, Cuba, 
Ecuador, Germany, Italy, and Spain) (Fig. 1).  
Epidemiologic and clinical profiles
The median age was 67 years (IQR 53.0–78.0), 
and most were male (60%). The most frequent co-
Figure 1. Study flow diagram.
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morbidities were hypertension (49%) and dyslipi-
demia (35.1%). A relevant heart disease [13] was 
recorded in 682 (24%) cases. Further details are 
displayed, stratified by the presence of any heart 
disease or not, in Table 1. In the heart-disease 
cohort, deceased heart patients were older (p < 
< 0.001) and more frequently male (58.5% vs. 
65.8%, p = 0.001), with a higher overall burden 
of cardiovascular risk factors (hypertension, dys-
lipemia, diabetes mellitus, smoking habit, obesity, 
p < 0.01 for all) and other comorbidities such 
as chronic renal failure, any lung disease, cere-
brovascular disease and oncologic antecedent 
(p < 0.01, for all). 
Regarding previous treatments, signs and 
symptoms, Table 1 displays the main findings, 
compared with patients without heart disease. 
In addition, Table 2 presents the main analytic 
findings at the time of admission and in hospital 
management strategies. Chest X-ray exhibited any 
acute lung abnormality in more than 70%, mostly 
bilateral (57.6%). In this setting, heart patients 
needed more respiratory and circulatory support 
and presented higher in hospital events (Table 3). 
The specific drug most frequently used was hy-
droxychloroquine (72%), followed by antibiotics 
and any antiviral drug (mostly lopinavir/ritonavir). 
Nevertheless, the heart disease group received 
a different pattern of treatment, characterized by 
more systemic corticoids, antibiotics, but less hy-
droxychloroquine, antivirals or tocilizumab (Table 2).
Influence of a previous heart condition
Assessing the whole sample epidemiologic 
profile, gender (male), age (increasing) and the 
presence of hypertension, dyslipemia, diabetes 
mellitus, obesity (body mass index > 30), renal 
insufficiency, any lung disease, any heart disease, 
previous cerebrovascular condition, connective or 
liver disease, any cancer or immunosuppressive 
condition displayed a significantly higher mortality 
(p < 0.01 in all) in the univariate analysis. 
Considering these variables in the multivariate 
assessment (Table 4), the following factors were 
considered independent risk factors: age, hyperten-
sion, chronic renal failure, any cancer and any heart 
disease (hazard ratio [HR] 1.62; 95% confidence 
interval [CI] 1.29–2.03).  
Outcomes inside the heart disease cohort
Focusing on those with an underlying heart 
condition, these patients presented higher mortal-
ity (39.7% vs. 15.5%, non-adjusted odds ratio [OR] 
3.58; 95% CI 2.95–4.34; p < 0.001; Figs. 2, 3). 
Heart patients, also, suffered more frequent in-
hospital events, such as heart failure, acute renal 
failure, respiratory insufficiency, sepsis, systemic 
infammatory response syndrome and clinically rel-
evant bleedings, (all, p < 0.001). Table 3 discusses 
this further and depicts the raw in-hospital events 
regarding the type of relevant heart condition group.
In the multivariate analysis for mortality, con-
sidering only the heart disease group, the following 
were included in the final model: age 70 years or 
more, hypertension, diabetes mellitus, chronic 
renal failure, use of oral anticoagulants, Vitamin D 
supplements, myalgia/arthralgia, O2 saturation 
< 92%, decreased blood pressure, elevated D di-
mer, elevated C reactive protein, elevated lactate 
dehydrogenase (LDH), invasive mechanical ven-
tilation, prone during admission, use of corticoids, 
hydroxychloroquine and angiotensin converting 
enzyme inhibitors/angiotensin receptor blockers 
(ACEIs/ARBs) during admission. Tachypnea and 
use of high flow nasal cannulas were excluded for 
potential collinearity with other variables (O2 satu-
ration and mechanical ventilation). Of those, age 
(HR 4.3; 95% CI 2.23–8.28), hypertension (HR 1.7; 
95% CI 1.01–2.89), O2 saturation < 92% (HR 3.59; 
95% CI 2.43–5.31), an elevated LDH (HR 1.66; 
95% CI 1.01–2.73), the use of mechanical ventila-
tion (HR 2.11; 95% CI 1.17–3.80) remained in the 
model as risk factors while the use of in hospital 
ACEIs/ARBS (HR 0.34; 95% CI 0.20–0.49) and 
hydroxychloroquine (HR 0.69; 95% CI 0.45–0.99) 
resulted as potential protective factors. 
Discussion
The present study is a cohort study among 
patients with COVID-19 after discharge, reviewing 
the direct impact on mortality of previous heart 
diseases. 
Regarding COVID-19, any kind of heart dis-
ease is probably a truly relevant condition. First, 
because compared to the general population, 
the incidence of cardio-cerebrovascular disease 
in patients with COVID-19 is much higher [14]. 
Second, because patients with hypertension, 
cardio-cerebrovascular diseases or diabetes are 
more likely to develop into severe/intensive care 
unit (ICU) cases or die after SARS-CoV-2 infection 
[5, 7, 14]. The overall proportion of hypertension, 
cardio-cerebrovascular problems and diabetes were 
about two-fold, three-fold and two-fold, respec-
tively, higher in ICU/severe cases than in their 
non-ICU/severe counterparts [14]. In the present 
cohort, it was observed that outcomes of patients 
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Table 1. Clinical features, previous treatments and presentation symptoms before admission overall 





Absent (N = 2116)   Present (N = 682)
No./total no. (%)
Age [years]
Median (IQR) [years] 
Distribution [years]: 
   0–14
   15–49
   50–64
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Table 1 (cont.). Clinical features, previous treatments and presentation symptoms before admission 





Absent (N = 2116)   Present (N = 682)
No./total no. (%)
Dependency level:
   Not disclosed
   None
   Partially






















































































Tachypnea (> 22 bpm)







































































O2 saturation < 92%








Abnormal BP (SBP < 90/< 60 mmHg)








*Some data are missing at the time of interim analysis. Calculations and percentages are expressed upon the recorded data as are displayed 
in the table (recorded/total available). 
**Comparisons and p values are applied to heart disease absence or presence. 
ACEI/ARB — angiotensin converting enzyme inhibitors/angiotensin receptors blockers; ASA — acelylsalicylic acid; BMI — body mass index; 
BP — blood pressure; CRI — chronic renal insufficiency; COPD — chronic obstructive pulmonary disease; SBP — systolic blood pressure
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Table 2. Relevant analytical results (early at admission) and in hospital management regarding the 




Absent (N = 2116) Present (N = 682)
Elevated D dimer

















Elevated C reactive protein


























Elevated creatinine (> 1.5 mg/dL)








White count cell (≤ 4000/µL)








Lymphocytes count (≤ 1500/µL)








Hemoglobin levels (≤ 12 g/dL)








Platelet counts (≤ 150,000/µL)









High flow nasal cannula

























































































Use of ACEIs/ARBs during stay








*Some data are missing at the time of interim analysis. Calculations and percentages are expressed upon the recorded data as are displayed 
in the table (recorded/total available). 
**Comparisons and p values are applied to heart disease absence or presence.
ACEI/ARB — angiotensin converting enzyme inhibitors/angiotensin receptors blockers; ECMO — extracorporeal membrane oxygenation;  
LDH — lactate dehydrogenase
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Table 4. Variables remaining in the model regarding mortality (multivariate analysis by Cox regression; 
backward: Wald)*. 
Characteristic Hazard ratio 95% confidence interval P
Age 70 years or more 4.05 3.02–5.42 < 0.001
Hypertension 1.39 1.07–1.81 0.013
Any heart condition 1.62 1.29–2.03 < 0.001
Chronic renal failure 1.80 1.38–2.37 < 0.001
Any cancer 1.36 1.06–1.76 0.016
Any cerebrovascular condition 1.30 0.98–1.74 0.070
Variables included in the clinical model*: For modeling purposes, at this point only age, gender and relevant comorbidities were considered. 
Thus, those variables with p values< 0.05 regarding mortality were included in the multivariate analysis. The variables accepted were: age  
70 years or more, gender, race, hypertension, dyslipemia, diabetes mellitus, obesity, chronic renal failure, any lung disease, cerebrovascular 
conditions, any heart disease, connective disease, any cancer, immunosuppressive condition, and any liver disease. The reference value was 
the absence of the precise condition. Previous medications were excluded for potential collinearity with the other mentioned variables  
(comorbidities)
Figure 2. The Kaplan-Meier survival analysis stratifying for gender and age; T0 = admission date; Considering only 
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with any heart disease were clearly worse regard-
ing mortality and other in-hospital complications. 
Overall, these findings suggest that preexisting 
heart problems marked a frailty point for COVID-19 
patients warranting close surveillance, intensive 
management and were considered low threshold 
for admission. 
On the other hand, at least 8.0% of COVID-19 
patients suffered any kind of acute cardiac injury, 
but further analysis pointed out that the incidence 
of myocardial injury is much higher in ICU/severe 
patients, about 13-fold more than non-ICU/cardiac 
patients [9, 14].
Obviously, part of this frailty can be explained 
because of a different clinical profile (elderly, more 
cardiovascular risk factors, renal disease and other 
COVID-19 factors) among heart and no-heart dis-
ease cohort, but not entirely. Altogether, heart 
disease seems to be primarily a risk factor for bad 
prognosis in COVID-19 [15]. This way, usually 
cardiovascular involvement measured by troponin 
levels and cardiovascular complications are higher 
in heart disease patients, as we observed in HOPE.
This is expected because it has been reported 
that the COVID-19, which supposes a severe global 
aggression, could primarily involve the heart and 
cardiovascular systems. Several mechanisms are 
at play in this regard, either by direct or indirect 
mechanisms, in adults but also in infants [11, 15]. 
Anyway, elevated cardiac troponin seems to point 
toward a worse prognosis [16]. 
The viral (SARS-CoV-2) infection is prompted by 
the binding of the virus’ spike protein to angiotensin-
converting enzyme 2 (ACE2) [16]. The expression of 
this ACE2 in the heart has been described to be lower 
than that in other organs, such as the intestine and 
kidney, but higher than in the lung which serves as 
a main target organ of the virus, indicating a potential 
infection susceptibility of the human heart [17, 18]. In 
some specific circumstances, this heart susceptibility 
could be theoretically higher, since ACE2 expression 
has been reported to be significantly increased in 
patients with heart failure, post myocardial infarction 
and diabetes [18–20]. 
Some of the proposed pathophysiological 
mechanisms would be: 
0.0 0.0
0 05 510 10
Days Days
Log rank = 168,546
P < 0.001
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Figure 3. Kaplan-Meier survival landmark analysis; T0 = admission date; A. Assessing no heart disease vs. any type 
of heart condition; B. Same comparison but regarding type of heart diseases. 
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 — Direct heart damage. Viral infection directly 
causes damage to cardiomyocyte. According 
to Oudit et al. [21], SARS-CoV viral RNA was 
detected in 35% of autopsied human heart 
samples from SARS-CoV infected patients 
during the past Toronto SARS outbreak. Of 
note, SARS-CoV and SARS-CoV-2 present 
high structural similarity between their re-
ceptor-binding domains [22]. Additionally, 
virus-infected cells can be injured, subse-
quently disturbing the micro-environment of 
the myocardium. SARS-CoV-2 infection in the 
human heart might attack pericytes as well, 
produce endothelial shedding and cause capil-
lary dysfunction and induce micro-circulation 
disorders [15, 18]. In our series, the specific 
type of heart disease with higher mortality 
with frequent in-hospital complications was 
heart failure/myopathy suggesting that struc-
turally weaker hearts could pose higher frailty. 
 — Hypoxia-induced myocardial injury. Because 
of lung pathology, pneumonia, respiratory dis-
tress syndrome, or the previously mentioned 
macro or micro vessel direct toxicity [15]. This 
condition, decreases the cell energy supply, 
leading to anaerobic fermentation, producing 
intracellular acidosis and oxygen free radicals 
to dismantle the phospholipid layer of the cell 
membrane. Moreover, hypoxia-induced influx 
of calcium also primes to injury and apoptosis 
of cardiac cells [15]. 
 — Production of procoagulant factors predispos-
ing to thrombosis, similar to the increase of 
myocardial infarctions reported after influenza 
infection [15, 23]. In fact, abnormal coagulation 
parameters and disseminated intravascular 
coagulation has been noted in COVID-19 [15] 
potentially contributing to damage the myocar-
dium through thrombosis or ischemic events. 
 — Local inflammation. Although there are early 
reports of myocarditis [24], even fulminant, the 
exact mechanism is not clear, since lympho-
cyte infiltrates were not found in COVID-19 
patients’ autopsy [15, 25].  
 — Probably, a significant depletion and dysregula-
tion of T cells can probably contribute to the 
cytokine storm (increased IL-2, IL-6, IL-10, 
GCSF, IFN-g, MCP-1 and TNF-a) leading to 
the multiorgan damage setting depicted in 
COVID-19. Cardiac damage by this deleterious 
condition could be analogous to that reported 
in CAR-T (chimeric antigen receptor T cell 
therapies used in relapsing hematological 
malignancies). 
Finally, last but not least, many specific drugs 
used for COVID-19 can cause cardiac side effects, 
arrhythmias or other cardiovascular disorders 
(hydroxychloroquine, antivirals, antibiotics, some 
immunomodulators). Different drug patterns were 
found when comparing patients with and without 
heart conditions. Therefore, during treatment of 
this condition, especially with the use of certain 
drugs, the risk of cardiac toxicity must be closely 
monitored, but to avoid depriving heart patients 
of potentially beneficial treatments. On the other 
side, special attention should be given to cardio-
vascular protective measures during management 
of COVID-19, since those patients have high risk 
of complications [13, 25–27]. In this aspect, the 
crucial role of ACEIs/ARBs needs to be taken 
into account [9, 10, 28, 29]. Despite under scien-
tific review, preliminary data seem to warrant its 
maintenance in patients already on these meds at 
admission. Additionally, the present findings dis-
play a potential mortality benefit when maintaining 
these treatments in this setting (OR 0.34; 95% CI 
0.20–0.49; p < 0.001; Table 4).
Limitations of the study
The main limitation is set by the study ob-
servational design and selecting only cases with 
higher risk profile or severe forms needing hos-
pital admission. In addition, the definition of the 
variables, the specific type and degree of heart 
disease and the reporting for the events could 
present certain grade of variation among cent-
ers, countries and the precise moment in their 
pandemic curve. However, this would probably 
reflect the variation that medical practice has in 
real life. About the treatment applied, at all times 
it was decided by the attending physician. While 
these observations give us an overall idea of the 
treatment of the disease in this precise cohort, 
they do not produce information as robust as 
a clinical trial would do [30]. 
Thus, the only aim was to generate hypoth-
eses; nevertheless, HOPE’s present analysis 
probably reveals a pragmatic depiction of the 
outcomes and prognosis of patients with prevalent 
heart conditions who are admitted with COVID-19, 
a challenge for modern medicine [30, 31].
Conclusions
An underlying heart disease is an adverse 
prognostic factor for patients suffering COVID-19. 
Its presence could be related with varying clinical 
drug management and could benefit from main-
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taining treatment with ACEIs or ARBs during 
in-hospital stay.  
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